文献速递支持与姑息治疗

个人基因组检测用于癌症风险:个人基因组检测影响研究的结果

Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study.
PubMed 文献 · J Clin Oncol · 2016-12-12

该纵向调查研究向23andMe和Pathway Genomics的新客户发放基线及6个月随访问卷,共762名有完整癌症相关数据的客户纳入分析。大多数客户因想了解癌症遗传风险而检测,但收到单核苷酸多态性(SNP)法升高癌症风险估计的少数客户在6个月时饮食、锻炼、预立医疗计划或癌症筛查行为与平均或降低风险者无显著差异。

要点

  • 在762名完成6个月随访的客户中,无客户检测出高外显率癌症易感基因的致病突变。
  • 收到SNP法升高癌症风险估计的客户在6个月时未显著更可能改变饮食、锻炼、预立计划或参与癌症筛查。
  • 收到前列腺癌风险升高的男性比平均或降低风险者更可能改变维生素和补充剂使用(22% vs 7.6%;调整OR 3.41;95%CI 1.44-8.18)。

核心结论

  • 大多数收到直接面向消费者个人基因组检测SNP法升高癌症风险估计的成人未显著改变饮食、锻炼、预立医疗计划或癌症筛查行为。

研究设计与样本

  • 纵向调查向23andMe和Pathway Genomics的新客户发放基线及6个月随访问卷,通过安全数据传输将调查数据与个体水平PGT结果链接。
  • 1,042名客户完成基线和6个月调查(应答率71.2%),其中762名有完整癌症相关数据并纳入分析。

主要发现

  • 大多数客户报告了解癌症遗传风险是检测动机(结直肠癌88%,前列腺癌95%,乳腺癌94%)。
  • 无客户检测出高外显率癌症易感基因的致病突变。
  • 少数个体收到SNP法升高的癌症风险估计(结直肠癌24%,前列腺癌24%,乳腺癌12%)。
  • 6个月时,收到升高PGT癌症风险估计的客户与平均或降低风险者相比,未显著更可能改变饮食、锻炼、预立计划行为或参与癌症筛查。
  • 收到升高前列腺癌风险估计的男性比平均或降低风险者更可能改变维生素和补充剂使用(22% vs 7.6%;调整OR 3.41;95%CI 1.44-8.18)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Significant concerns exist regarding the potential for unwarranted behavior changes and the overuse of health care resources in response to direct-to-consumer personal genomic testing (PGT). However, little is known about customers' behaviors after PGT. Methods Longitudinal surveys were given to new customers of 23andMe (Mountain View, CA) and Pathway Genomics (San Diego, CA). Survey data were linked to individual-level PGT results through a secure data transfer process. Results Of the 1,042 customers who completed baseline and 6-month surveys (response rate, 71.2%), 762 had complete cancer-related data and were analyzed. Most customers reported that learning about their genetic risk of cancers was a motivation for testing (colorectal, 88%; prostate, 95%; breast, 94%). No customers tested positive for pathogenic mutations in highly penetrant cancer susceptibility genes. A minority of individuals received elevated single nucleotide polymorphism-based PGT cancer risk estimates (colorectal, 24%; prostate, 24%; breast, 12%). At 6 months, customers who received elevated PGT cancer risk estimates were not significantly more likely to change their diet, exercise, or advanced planning behaviors or engage in cancer screening, compared with individuals at average or reduced risk. Men who received elevated PGT prostate cancer risk estimates changed their vitamin and supplement use more than those at average or reduced risk (22% v 7.6%, respectively; adjusted odds ratio, 3.41; 95% CI, 1.44 to 8.18). Predictors of 6-month behavior include baseline behavior (exercise, vitamin or supplement use, and screening), worse health status (diet and vitamin or supplement use), and older age (advanced planning, screening). Conclusion Most adults receiving elevated direct-to-consumer PGT single nucleotide polymorphism-based cancer risk estimates did not significantly change their diet, exercise, advanced care planning, or cancer screening behaviors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gray SW, Gollust SE, Carere DA, et al. Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. J Clin Oncol. 2016. PMID: 27937091. doi:10.1200/JCO.2016.67.1503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。